2030 Related Topics 
Drug Patent Watch
DECEMBER 10, 2024
from 2023 to 2030. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 billion in 2022 and is expected to grow at a compound annual growth rate of 5.3%
LifeSciVC
MAY 14, 2025
Demand exceeds supply, and there is little hope in clearing the queue many ongoing studies wont even finish prior to the ISSs 2030 retirement. Access to and reliance on the ISS is a bottleneck. 6 That opportunity hasnt gone unnoticed by a burgeoning private space industry. 9 Keytruda, for example, sports a list price of $47M per kg.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
DECEMBER 11, 2024
Future Directions and Strategies By 2030, generics manufacturers will need to shift from the status quo and explore new avenues for change. Generics 2030: Three Strategies to Curb the Downward Spiral. This includes developing higher-value generics, investing in innovation, and creating differentiated products.
Broad Institute
JUNE 24, 2025
With the right framework and the right support, I believe it will be possible to treat at least 1,000 patients with personalized genetic treatments by 2030. The challenge is that even when the science is successful, that doesn't guarantee an economically viable path to bring these new medicines to the patients who need them.
The Pharma Data
JUNE 13, 2025
2026–2030). This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. Today, the Programme stands at a turning point, as it moves into its Phase 2.0
Codon
NOVEMBER 3, 2024
But they will need to do so if they want to meet the goals set out by the End TB Strategy , namely, to reduce TB cases by 80 percent and curb deaths by 90 percent before 2030. As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers.
SugarCone Biotech
JULY 6, 2025
Reporting in Nature Reviews Drug Discovery, @AsherMullard noted that Merus must provide the FDA with confirmatory evidence of benefit in both NSCLC and pancreatic adenocarcinoma in order to achieve full approval and that analysts predict annual sales of around $180 million by 2030 per consensus forecast via Cortellis.
Expert insights. Personalized for you.
85 
Let's personalize your content